BioXcel Therapeutics (NASDAQ:BTAI) Rating Reiterated by HC Wainwright
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 269.00% from the stock’s current price. BTAI has […]
More Stories
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX)
Equities research analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a note issued...
StockNews.com Begins Coverage on Trio-Tech International (NYSE:TRT)
Analysts at StockNews.com began coverage on shares of Trio-Tech International (NYSE:TRT – Get Free Report) in a report released on...
Kate Dehoff Sells 6,205 Shares of Joby Aviation, Inc. (NYSE:JOBY) Stock
Joby Aviation, Inc. (NYSE:JOBY – Get Free Report) insider Kate Dehoff sold 6,205 shares of the stock in a transaction...
Truist Financial Has Lowered Expectations for International Game Technology (NYSE:IGT) Stock Price
International Game Technology (NYSE:IGT – Get Free Report) had its target price lowered by Truist Financial from $23.00 to $20.00...
Rostislav Christov Raykov Buys 19,200 Shares of Lavras Gold Corp. (CVE:LGC) Stock
Lavras Gold Corp. (CVE:LGC – Get Free Report) Director Rostislav Christov Raykov bought 19,200 shares of the firm’s stock in...
Morgan Stanley Has Lowered Expectations for Illumina (NASDAQ:ILMN) Stock Price
Illumina (NASDAQ:ILMN – Free Report) had its price objective decreased by Morgan Stanley from $156.00 to $150.00 in a research...